Literature DB >> 10986566

In vitro selection of lentivirus vector-transduced human CD34+ cells.

J Gatlin1, J Douglas, J T Evans, R H Collins, G D Wendel, J V Garcia.   

Abstract

Human CD34(+) cells with in vivo repopulating potential hold much promise as a target for corrective gene transfer for numerous hematopoietic disorders. However, the efficient introduction of exogenous genes into this small, quiescent population of cells continues to present a significant challenge. To circumvent the need for high initial transduction efficiency of human hematopoietic cells, we investigated a dominant selection strategy using a variant of the DHFR gene (DHFR(L22Y)). For this purpose, we constructed a lentivirus-based bicistronic vector expressing EGFP and DHFR(L22Y). Here we demonstrate efficient in vitro selection and enrichment of lentivirus vector-transduced human CD34(+) hematopoietic cells from fetal liver, umbilical cord blood, bone marrow, and peripheral blood after cytokine mobilization. Growth of transduced human CD34(+) cells in semisolid culture under selective pressure resulted in enrichment of transduced progenitor cells to 99.5% (n = 14). Selection for DHFR(L22Y)(+) cells after expansion of transduced progenitors in liquid culture resulted in a 7- to 13-fold increase in the percentage of marked cells. Thus we have shown that transduced human hematopoietic cells may be effectively enriched in vitro by dominant selection, suggesting that development of such strategies holds promise for future in vivo application.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986566     DOI: 10.1089/10430340050129558

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  3 in total

1.  Engraftment of NOD/SCID mice with human CD34(+) cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein.

Authors:  J Gatlin; M W Melkus; A Padgett; P F Kelly; J V Garcia
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.

Authors:  Mahesh Jonnalagadda; Christine E Brown; Wen-Chung Chang; Julie R Ostberg; Stephen J Forman; Michael C Jensen
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

3.  Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Authors:  M Jonnalagadda; C E Brown; W C Chang; J R Ostberg; S J Forman; M C Jensen
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.